3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
aldesleukin
134
Cyclophosphamide
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
67
dabrafenib
65
fludarabine phosphate
61
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
cobimetinib
32
Magnetic Resonance Spectroscopy
32
Introns
30
Specimen Handling
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
Isoflurane
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled